A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic

Enzymatica announces today the preliminary results of an in vitro study showing the ability of the mouth spray ColdZyme® to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic. The study demonstrated that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3% (1.76 log₁₀). The results indicate that ColdZyme can offer a protective barrier against harmful viruses such as SARS-CoV-2 by local virus deactivation in the oral cavity.

The medical device ColdZyme is a mouth spray that forms a barrier in the oral cavity against common cold viruses. The barrier solution of the device is mainly composed of glycerol and Atlantic cod trypsin. The goal of the present study was to determine the ability of ColdZyme to deactivate SARS-CoV-2 known to cause the COVID-19 pandemic. A virucidal efficacy suspension test was conducted using ColdZyme against SARS-CoV-2. ColdZyme deactivated SARS-CoV-2 by 98.3% (1.76 log₁₀) in 20 minutes. Furthermore, no cytotoxicity was detected for ColdZyme at any dilution tested. The study was conducted by the US company Microbac Laboratories Inc - an independent, accredited and certified laboratory.

The in vitro study was based on a standardized and validated methodology, i.e. ASTM International test method designated E1052 “Standard Test Method to Assess the Activity of Microbicides against Viruses in Suspension”.

Previous in vitro results made with the same method showed that ColdZyme is effective against another coronavirus, HCoV-229E, one of the causes of the common cold, and in comparison to SARS-CoV-2 belongs to another subgroup within the corona family. The aggregated results indicate that ColdZyme can be effective against a variety of coronaviruses.

SARS-CoV-2 actively replicates in the throat and shows high viral shedding also at a time of mild symptoms. Therefore, ColdZyme sprayed onto the mouth and throat could lower the risk of infection, and decrease the viral load locally. Lowered viral load may decrease viral shedding and thus minimize the spread of SARS-CoV-2.

"Even if the current in vitro results cannot be directly translated into clinical efficacy, it is very interesting that ColdZyme is able to effectively deactivate SARS-CoV-2 in vitro since it constitutes a proof-of-principle that can be taken further into clinical studies. Thus, the results indicate that ColdZyme can offer a protective barrier against SARS-CoV-2," says Claus Egstrand, Enzymatica’s Chief Operating Officer.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8.30 am CET on July 20, 2020.

FOR MORE INFORMATION, PLEASE CONTACT:
Claus Egstrand, Chief Operating Officer Enzymatica AB
Phone: +44 7780 22 8385 | E-mail: claus.egstrand@enzymatica.com

Bengt Baron, Executive Chairman of the Board, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: bengt.baron@outlook.com
ABOUT ENZYMATICA AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica’s certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se